<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616040</url>
  </required_header>
  <id_info>
    <org_study_id>LION-EC</org_study_id>
    <nct_id>NCT04616040</nct_id>
  </id_info>
  <brief_title>A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer</brief_title>
  <official_title>A Non-interventional Registration Study Evaluating the Usage of Camrelizumab in the Treatment of Unresectable Locally Advanced/Recurrent or Metastatic Chinese Patients With Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multi-center, open, observational registration study, which aims to evaluate&#xD;
      the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese&#xD;
      patients with advanced esophageal cancer in the real world.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Adverse events of Camrelizumab</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>especially Occurrence of ≥Grade 3 immune-related AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events of Camrelizumab</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>including other occasional or rare AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>Duration from the date of initial treatment to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>A duration from the date of initial treatment to radiographic disease progression or death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>Proportion of objective complete response and partial response patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlations between biomarkers and clinical activity</measure>
    <time_frame>an expected average of 24 months</time_frame>
    <description>tumor biopsies are collected before start of treatment, for assessing the relationship between different biomarkers (e.g. PD-L1 expression) with different camrelizumab-based regimens</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1030</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>unresectable locally advanced/recurrent or metastatic esophageal cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.</description>
    <arm_group_label>unresectable locally advanced/recurrent or metastatic esophageal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        unresectable locally advanced/recurrent or metastatic esophageal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign informed consent and voluntarily participate in this study.&#xD;
&#xD;
          2. Unresectable locally advanced/recurring or distant metastatic esophageal cancer&#xD;
             patients confirmed by histology or cytology (AJCC 8th edition);&#xD;
&#xD;
               -  Unresectable locally advanced patients who are unable or unable to receive&#xD;
                  radical treatment (including radical radio chemotherapy or radical radiotherapy,&#xD;
                  etc.) may be considered for inclusion;&#xD;
&#xD;
               -  Patients who progress or relapse after neoadjuvant or adjuvant therapy may also&#xD;
                  be considered for inclusion;&#xD;
&#xD;
          3. Age ≥ 18 years old;&#xD;
&#xD;
          4. The investigator determines that the patient can receive Camrelizumab as a single&#xD;
             agent or combination therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence suggests that the patient is pregnant or breastfeeding;&#xD;
&#xD;
          2. Other drug blinded clinical trials are currently underway;&#xD;
&#xD;
          3. Other situations that are not suitable for inclusion in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 1, 2020</last_update_submitted>
  <last_update_submitted_qc>November 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

